Summer Undergraduate Internship - Translational Medicine
Summer Internships | Berkeley, CA | Internship
This is a summer internship for undergraduate students who will still be in an undergraduate program in the Fall of 2018.
The Translational Medicine Intern will contribute in two different roles:
The primary role/project comprises the design and execution of experiments that validate and streamline biomarker assays for upcoming clinical trials. Previous studies with several of Plexxikon’s lead compounds have identified rational pharmacodynamic (PD) biomarkers that are detectable in blood. The next step will be to confirm the involvement of the target protein and then identify and test an assay suitable for clinical PD analysis.
A secondary role/function will be to assist with collection and organization of preclinical data generated by Plexxikon’s collaborators. As part of Plexxikon’s discovery and development model we have established hundreds of collaborations in which we share our proprietary molecules with investigators in exchange for generating data that is mutually beneficial. The intern’s responsibilities will include: assisting with transfer of research materials, compiling concise data summaries and communicating with outside collaborators.
At the end of the internship a final presentation will be given at the company Research Meeting to demonstrate the results of biomarker assay validation and other achievements.
Candidates for the internship must be a rising junior in a Bachelor program in Molecular Biology, Genetics or related field. He or she should have a solid understanding of experimental design, statistics and excellent communication skills. Some lab experience with nucleic acid extraction, QPCR, immunoprecipitation and next-generation sequencing is preferred.
Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company utilizes its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage compounds in a number of therapeutic areas. Plexxikon’s most advanced program, Zelboraf™ (vemurafenib) was the first oral targeted therapy to be approved for the treatment of both metastatic and unresectable melanomas. Plexxikon's demonstrated capability in discovery and early development uniquely positions the company to develop multiple commercial franchises for different therapeutic indications, and to create significant value for Plexxikon, Daiichi Sankyo and its collaborators.
Plexxikon's novel discovery approach, combined with experienced management and scientific teams, a broad network of scientific and clinical experts, and partnerships supporting later stage development, have been key drivers of the company's success since it began operations in 2001. Plexxikon is a small business with approximately 70 employees based in Berkeley, California.
Summer 2018 will be Plexxikon’s fourteenth year of participation in the undergraduate summer internship program, having experienced highly successful results in each previous year. This is a paid internship that will run from Friday, June 1 – Friday, August 11, 2018. Our office is just off I80 at University Avenue. Please find out more at: www.plexxikon.com.